1-13 of 13
Carla Boquimpani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Andreas Hochhaus, Philipp le Coutre, Dragana Milojkovic, Dennis Dong Hwan Kim, Soo Min Lim, Carolina Pavlovsky, Thanh HA Nguyen, Franck E. Nicolini, Beatriz Moiraghi, Sebastian Grosicki, Chi Dung Phu, Gabriel Etienne, Fernando Marco De Lucas, Rosa Ayala, Massimo Breccia, Charles Chuah, Giora Sharf, Roberto Abi Rached, Himanshu Pokhriyal, Santoshkumar Tota, Asmae Mirkou, Peter Schuld, Carla Boquimpani
Journal: Blood
Blood (2024) 144 (Supplement 1): 4526.
https://doi.org/10.1182/blood-2024-200017
Published: 2024
Journal Articles

External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry

Irene Biasoli, Valeria Buccheri, Frederico Rafael Moreira, Nelson Castro, Carolina Colaço Vilarim, Fabiola Traina, Carlos Chiattone, Monica Praxedes, Cristiana Solza, Leila Perobelli, Otavio Baiocchi, Rafael Gaiolla, Carla Boquimpani, Caroline Bonamin Sola, Roberta Oliveira P Silva, Ana Carolina Ribas, Katia Pagnano, Giovanna Steffenello, Carmino De Souza, Nelson Spector, Angie Mae Rodday, Jenica Upshaw, Matthew J. Maurer, Andrew M Evens, Susan K Parsons
Journal: Blood
Blood (2023) 142 (Supplement 1): 6200.
https://doi.org/10.1182/blood-2023-173318
Published: 2023
Journal Articles

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Michael Mauro, Jorge E. Cortes, Jane F. Apperley, Valentín García Gutiérrez, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus
Journal: Blood
Blood (2022) 140 (Supplement 1): 6757–6759.
https://doi.org/10.1182/blood-2022-169110
Published: 2022
Journal Articles

ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors

Massimo Breccia, Anna Turkina, Carla Boquimpani, Charles Chuah, Giora Sharf, Luigi Di Caprio, Matthias Hoch, Justin Yssel, Yifan Zhang, Andreas Hochhaus
Journal: Blood
Blood (2022) 140 (Supplement 1): 9635–9636.
https://doi.org/10.1182/blood-2022-157991
Published: 2022
Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Clinical Trials & Observations
Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentin García-Gutiérrez, Jorge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
Journal: Blood
Blood (2021) 138 (21): 2031–2041.
https://doi.org/10.1182/blood.2020009984
Published: 2021
Includes: Supplemental data
Journal Articles

Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey

Zack Pemberton-Whiteley, Jorge E. Cortes, Joannie Clements, Cristina Ruiz, Delphine Rea, Lisa Machado, Fabian Lang, Naoto Takahashi, Nigel Deekes, Sung-Ho Moon, Andrew Grigg, Merula Steagall, Cornelia Borowczak, Virginia Pilipovic, Pauline Frank, Cristina Constantinescu, Carla Boquimpani
Journal: Blood
Blood (2021) 138 (Supplement 1): 4986.
https://doi.org/10.1182/blood-2021-147739
Published: 2021
Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Michael J. Mauro, Yosuke Minami, Delphine Rea, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong-Wook Kim, Jane F Apperley, Jorge E. Cortes, Andre N.R. Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp D le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín Garcia Gutierrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Carla Boquimpani
Journal: Blood
Blood (2021) 138 (Supplement 1): 310.
https://doi.org/10.1182/blood-2021-152561
Published: 2021
Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, MD, Carla Boquimpani, MD, Delphine Rea, MDPhD, Yosuke Minami, MDPhD, Elza Lomaia, MD PhD, Sergey Voloshin, MD PhD, Anna G. Turkina, Prof., MD, Dong-Wook Kim, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Andre Abdo, MD, Laura Maria Fogliatto, MD PhD, Dennis Dong Hwan Kim, MD PhD, Philipp D le Coutre, MD, Susanne Saussele, MD, Mario Annunziata, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Naeem A. Chaudhri, MD, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA, Valentín García Gutiérrez, MD PhD, Koji Sasaki, MD, Paola Aimone, MD, Alex Allepuz, MD MPH, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-4.
https://doi.org/10.1182/blood-2020-143816
Published: 2020
Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Giuseppe Saglio, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Surapol Issaragrisil, MD, Philipp Le Coutre, MD, Gabriel Etienne, MD PhD, Carla Boquimpani, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Viviane Dubruille, MD, Ian W. Flinn, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Ewa Medras, MD, Maria Zanichelli, MD, Israel Bendit, MD PhD, Manu Sondhi, MD PhD, Ksenia Titorenko, MS, Claire Nourry-Boulot, PhD, Paola Aimone, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2924.
https://doi.org/10.1182/blood-2019-128761
Published: 2019
Journal Articles

Resource Use and Costs Associated With The Treatment Of Hematologic and NON-Hematologic Adverse Events In Chronic Myeloid Leukemia (CML) Brazilian Patients

Marcia Dias Alves, MBA, Marta M. Lemos, MD, Carla Boquimpani, MD
Journal: Blood
Blood (2013) 122 (21): 5620.
https://doi.org/10.1182/blood.V122.21.5620.5620
Published: 2013
Journal Articles

Initial Molecular Response At 3 Months Can Identify Three Groups Of Patients With Different Responses and Event-Free Survival At 36-Months Following Second-Generation Tyrosine Kinase Inhibitor Therapy In Imatinib-Resistant Chronic Myeloid Leukemia

Carla Boquimpani, MD, Rony Schaffel, MD, PhD, Daniel Graça, Camila Mesquita, Tania Silva Madeira, MD, Danielle Peixoto, MD, Patricia Wendling, MD, Clarisse Lobo, MD, Irene Biasoli, MD, PhD, Nelson Spector, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4005.
https://doi.org/10.1182/blood.V122.21.4005.4005
Published: 2013
Journal Articles

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

Katia B. Pagnano, MD, Israel Bendit, MD, Carla Boquimpani, Carmino Antonio De Souza, MD, PhD, Eliana C M Miranda, Rosana A Silveira, Vaneuza A M Funke, MD, Ricardo Pasquini, MD, Vania Hungria, MD, Nelma Clementino, MD, Monika Conchon, Elena B Moiraghi, MD, Jose L. Lopez, MD, Carolina Pavlovsky, MD, Eduardo Cervera, Belinda Pinto Simoes, MD, PhD, Luis A Meillon, MD, Nelson Spector, MD, PhD, Nelson Hamerschlak, MD, Miguel Pavlovsky, Alicia Magarinos, MD, Vagner O Duarte, Ernesto M Fanilla, Jorge E. Cortes, Raquel Bengió, MD
Journal: Blood
Blood (2011) 118 (21): 1701.
https://doi.org/10.1182/blood.V118.21.1701.1701
Published: 2011
Journal Articles

Comparasion Between Nilotinib and Dasatinib as Second-Line Therapy for Patients with Chronic Myeloid Leukemia: A Single Center Retrospective Study.

Clarisse Lobo, MD, Carla Boquimpani, Tania Silva Madeira, Patricia Wendling, Claudia Maximo, Carlos Bernardo Lima, Elias Atta, Renata DE SOUZA Cravo
Journal: Blood
Blood (2010) 116 (21): 3440.
https://doi.org/10.1182/blood.V116.21.3440.3440
Published: 2010